Research programme: next-generation interferon alpha and beta therapies - Maxygen/Roche

Drug Profile

Research programme: next-generation interferon alpha and beta therapies - Maxygen/Roche

Alternative Names: MAXY-24; Next-generation interferon alpha and beta therapies research programme - Maxygen/Roche

Latest Information Update: 10 Jun 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Maxygen
  • Developer Maxygen; Roche
  • Class Interferons
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hepatitis B; Hepatitis C

Most Recent Events

  • 26 Nov 2007 Discontinued - Preclinical for Hepatitis B in USA (unspecified route)
  • 26 Nov 2007 Discontinued - Preclinical for Hepatitis C in USA (unspecified route)
  • 28 May 2003 Preclinical trials in Hepatitis B treatment in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top